CLRB - 2.19 Pre-market now at 2.70/2.85 FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma https://stockcharts.com/c-sc/sc?s=CLRB&p=D&b=5&g=0&i=t74841115384&r=1537187766053